What is Supernus Pharmaceuticals, Inc. (SUPN) stock price today?

Supernus Pharmaceuticals, Inc. (SUPN) is currently trading at $42.91, up 1.83% today.

What is SUPN P/E ratio?

Supernus Pharmaceuticals, Inc.'s P/E ratio is -22.06. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is SUPN return on equity (ROE)?

Supernus Pharmaceuticals, Inc.'s return on equity (ROE) is -10.42%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Supernus Pharmaceuticals, Inc.'s market cap?

Supernus Pharmaceuticals, Inc. has a market capitalization of $2.49B.

NASDAQ · Drug Manufacturers - Specialty & Generic

Supernus Pharmaceuticals, Inc. (SUPN) Stock

$42.91 +1.83% NASDAQ: SUPN Healthcare

Valuation

Metric	Value
Price	$42.91
Market Cap	$2.49B
P/E Ratio	-22.06
P/B Ratio	2.39
P/S Ratio	2.96
EPS (TTM)	$-0.68
52-Week High	$59.68
52-Week Low	$40.51
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-10.42%
ROA	-7.69%
ROCE	-10.35%
Gross Margin	-5.15%
Operating Margin	-5.15%
Net Margin	-13.23%
Debt/Equity	0.04
Current Ratio	1.91

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$580.0M	$667.0M	$608.0M	$662.0M	$719.0M
Operating Profit	$86.0M	$46.0M	$-5.0M	$82.0M	$-37.0M
Net Profit	$53.0M	$61.0M	$1.0M	$74.0M	$-39.0M
EPS	$0.98	$1.04	$0.02	$1.32	$-0.68
Op Margin	14.8%	6.9%	-0.9%	12.3%	-5.1%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$1.7B	$1.7B	$1.3B	$1.4B	$1.5B
Total Liabilities	$873.0M	$816.0M	$356.0M	$332.0M	$391.0M
Cash	$203.0M	$93.0M	$75.0M	$69.0M	$128.0M
Borrowings	$427.0M	$445.0M	$42.0M	$34.0M	$41.0M

Latest News

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026 GlobeNewswire · Jul 22, 2026 SUPN: Raising target price to $45.00 Argus Research · Jul 22, 2026 1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm StockStory · Jul 16, 2026 1 Growth Stock to Stash and 2 We Turn Down StockStory · Jul 15, 2026 Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD GlobeNewswire · Jul 14, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$127.0M	$117.0M	$111.0M	$172.0M	$47.0M
Investing Cash Flow	$-84.0M	$-217.0M	$268.0M	$-191.0M	$3.0M
Financing Cash Flow	$0	$-23.0M	$-2.0M	$-3.0M	$-28.0M
Net Cash Flow	$-85.0M	$-110.0M	$-18.0M	$-6.0M	$61.0M
Free Cash Flow	$125.0M	$116.0M	$111.0M	$171.0M	$46.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.21
EV / EBITDA	-146.20
FCF Yield	0.76%
Quick Ratio	1.84
Interest Coverage	-48.30
Return 1Y	43.68%
Return 3Y	53.35%
Return 5Y	72.13%

Ownership

Insiders Held4.46%

Institutions Held102.87%

Institutions Float Held107.67%

Institutional Holder	Shares	Report Date
Blackrock Inc.	8,797,254	2026-03-31
Millennium Management Llc	3,315,973	2026-03-31
Vanguard Portfolio Management LLC	3,238,693	2026-03-31
Vanguard Capital Management LLC	2,467,215	2026-03-31
Dimensional Fund Advisors LP	2,307,030	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACADACADIA Pharmaceuticals Inc.	$19.88	+1.53%	8.87	$3.40B	0.00%
AVXLAnavex Life Sciences Corp.	$1.45	-5.68%	-6.96	$134.61M	0.00%
AXSMAxsome Therapeutics, Inc.	$169.38	-0.41%	-49.17	$8.72B	0.00%
DNLIDenali Therapeutics Inc.	$19.28	+3.24%	-7.04	$3.06B	0.00%
IONSIonis Pharmaceuticals, Inc.	$45.31	+4.63%	-12.57	$7.53B	0.00%

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. (SUPN) stock trades at $42.91 with a market capitalization of $2.49B. The stock is valued at a price-to-earnings (P/E) ratio of -22.06, price-to-book of 2.39, price-to-sales of 2.96. Over the past 52 weeks the stock has ranged between $40.51 and $59.68, and currently trades 28.1% below its 52-week high.

On profitability, Supernus Pharmaceuticals, Inc. generates a return on equity (ROE) of -10.42%, return on capital employed of -10.35%, an operating margin of -5.15%, a net profit margin of -13.23%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1173.15 +0.30% JNJ Johnson & Johnson $260.24 +1.47% ABBV AbbVie Inc. $276.46 +1.48% MRK Merck & Company, Inc. Common Stock (new) $146.28 +2.74% UNH UnitedHealth Group Incorporated Common Stock (DE) $381.63 +2.88% NVS Novartis AG $143.79 +0.47% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $657.30 +0.82% AMGN Amgen Inc. $416.42 +2.20% GILD Gilead Sciences, Inc. $150.73 +2.47% ABT Abbott Laboratories $99.51 +1.04% NVO Novo Nordisk A/S $38.42 +0.62%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides